AU2017376807B2 - Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device - Google Patents

Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device Download PDF

Info

Publication number
AU2017376807B2
AU2017376807B2 AU2017376807A AU2017376807A AU2017376807B2 AU 2017376807 B2 AU2017376807 B2 AU 2017376807B2 AU 2017376807 A AU2017376807 A AU 2017376807A AU 2017376807 A AU2017376807 A AU 2017376807A AU 2017376807 B2 AU2017376807 B2 AU 2017376807B2
Authority
AU
Australia
Prior art keywords
ingestible device
antibody
disease
ingestible
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017376807A
Other languages
English (en)
Other versions
AU2017376807A1 (en
Inventor
Mitchell Lawrence Jones
Sharat Singh
Harry Stylli
Christopher Loren WAHL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bt Bidco Inc
Original Assignee
Bt Bidco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bt Bidco Inc filed Critical Bt Bidco Inc
Publication of AU2017376807A1 publication Critical patent/AU2017376807A1/en
Assigned to BIORA THERAPEUTICS, INC. reassignment BIORA THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: PROGENITY INC.
Application granted granted Critical
Publication of AU2017376807B2 publication Critical patent/AU2017376807B2/en
Assigned to BT BIDCO, INC. reassignment BT BIDCO, INC. Request for Assignment Assignors: BIORA THERAPEUTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0097—Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0061—Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/073—Intestinal transmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
AU2017376807A 2016-12-14 2017-12-14 Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device Active AU2017376807B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662434348P 2016-12-14 2016-12-14
US62/434,348 2016-12-14
US201762478744P 2017-03-30 2017-03-30
US62/478,744 2017-03-30
US201762545188P 2017-08-14 2017-08-14
US62/545,188 2017-08-14
US201762583797P 2017-11-09 2017-11-09
US62/583,797 2017-11-09
PCT/US2017/066474 WO2018112232A1 (en) 2016-12-14 2017-12-14 Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device

Publications (2)

Publication Number Publication Date
AU2017376807A1 AU2017376807A1 (en) 2019-06-13
AU2017376807B2 true AU2017376807B2 (en) 2024-07-18

Family

ID=60953956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017376807A Active AU2017376807B2 (en) 2016-12-14 2017-12-14 Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device

Country Status (10)

Country Link
US (2) US11597762B2 (enExample)
EP (1) EP3554540B1 (enExample)
JP (2) JP7237834B2 (enExample)
KR (1) KR20190095931A (enExample)
CN (2) CN117045784A (enExample)
AU (1) AU2017376807B2 (enExample)
BR (1) BR112019011702A2 (enExample)
CA (1) CA3045475A1 (enExample)
MX (1) MX2019006823A (enExample)
WO (1) WO2018112232A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085330A1 (en) * 2017-12-14 2019-06-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a s1p modulator
JP6611833B2 (ja) * 2018-01-16 2019-11-27 キヤノン株式会社 放射線撮影システム、並びに、カメラ制御装置及びその制御方法
EP3810268A1 (en) * 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
FI13575Y1 (fi) * 2018-09-24 2024-03-26 Janssen Biotech Inc IL12/IL23-vasta-aine käytettäväksi turvallisessa ja tehokaassa menetelmässä haavaisen paksusuolitulehduksen hoitamiseksi
JP7657714B2 (ja) * 2018-11-15 2025-04-07 ヤンセン バイオテツク，インコーポレーテツド 炎症性腸疾患の治療に対する応答を予測するための方法及び組成物
CN109350599A (zh) * 2018-12-12 2019-02-19 辽宁新高制药有限公司 一种用于皮肤念球菌病治疗的喷雾剂
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN114555120A (zh) * 2019-10-18 2022-05-27 詹森生物科技公司 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
JP7444991B2 (ja) * 2019-12-16 2024-03-06 イーライ リリー アンド カンパニー 消化器サンプリングのためのカプセル
KR102391865B1 (ko) * 2020-04-03 2022-04-27 재단법인대구경북과학기술원 약물 전달 디바이스
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN112731954B (zh) * 2020-12-25 2024-06-21 深圳市优必选科技股份有限公司 机器人的运动控制方法、装置、机器人及存储介质
US20240316324A1 (en) * 2021-01-29 2024-09-26 Biograil ApS Drug delivery device with releasable attachment part
IL303862A (en) * 2021-01-29 2023-08-01 Biograil ApS Single attachment part drug delivery device
DK180991B1 (en) * 2021-01-29 2022-09-06 Biograil ApS Drug delivery device with carrier and insert
CN118176034A (zh) * 2021-10-28 2024-06-11 柏欧格瑞有限责任公司 高剂量药物输送装置
EP4197437A1 (en) * 2021-12-17 2023-06-21 Stichting IMEC Nederland Methods and devices for in vivo assessment of analytes in the gastrointestinal tract
CA3270918A1 (en) * 2022-10-17 2024-04-25 Rani Therapeutics Llc Dosage Forms and Methods of Ustekinumab
CN116027048A (zh) * 2023-02-06 2023-04-28 山东中鸿特检生物科技有限公司 一种细胞因子风暴综合征诊断试剂盒及其应用
WO2025235985A1 (en) * 2024-05-10 2025-11-13 University Of Southern California Ingestible sensor or treatment system and method with localization from magnetic-field generating wearable device

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4281645A (en) 1977-06-28 1981-08-04 Duke University, Inc. Method and apparatus for monitoring metabolism in body organs
US4190328A (en) 1978-12-01 1980-02-26 Levine Robert A Process for detection of blood-borne parasites
JPS5588732A (en) 1978-12-26 1980-07-04 Olympus Optical Co Endoscope
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
AU652540B2 (en) 1989-07-19 1994-09-01 Xoma Corporation T cell receptor peptides as therapeutics for autoimmune and malignant disease
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5279607A (en) 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US5314805A (en) 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
US5318557A (en) 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2679899A (en) 1998-02-18 1999-09-06 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
PT1108435E (pt) 1998-08-24 2007-04-30 Chugai Pharmaceutical Co Ltd Agentes preventivos ou terapêuticos para pancreatite contendo antagonistas da il-6 como ingrediente activo
US6331530B1 (en) 1999-07-13 2001-12-18 The Trustees Of Columbia University In The City Of New York Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen
US6703248B1 (en) 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
GB9930000D0 (en) 1999-12-21 2000-02-09 Phaeton Research Ltd An ingestible device
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20030117491A1 (en) 2001-07-26 2003-06-26 Dov Avni Apparatus and method for controlling illumination in an in-vivo imaging device
KR20040108655A (ko) 2002-03-05 2004-12-24 아클라라 바이오사이언시스 인코퍼레이티드 막-결합된 민감제를 사용하는 복합 분석법
US7797033B2 (en) 2002-04-08 2010-09-14 Smart Pill Corporation Method of using, and determining location of, an ingestible capsule
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
RU2334506C2 (ru) * 2003-01-29 2008-09-27 И-Пилл Фарма Лтд. Активная доставка лекарственного средства в желудочно-кишечном тракте
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7247711B2 (en) 2003-05-09 2007-07-24 Centocor, Inc. IL-23p40 specific antibody
EP1643906A2 (en) 2003-06-12 2006-04-12 University of Utah Research Foundation Apparatus, systems and methods for diagnosing carpal tunnel syndrome
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20050065441A1 (en) 2003-08-29 2005-03-24 Arkady Glukhovsky System, apparatus and method for measurement of motion parameters of an in-vivo device
JP4445732B2 (ja) 2003-08-29 2010-04-07 オリンパス株式会社 被検体内導入装置および無線型被検体内情報取得システム
JP2005074031A (ja) 2003-09-01 2005-03-24 Pentax Corp カプセル内視鏡
CN1874789A (zh) 2003-09-23 2006-12-06 光科学公司 用于光动力疗法的缀合物
US8206285B2 (en) 2003-12-31 2012-06-26 Given Imaging Ltd. Apparatus, system and method to indicate in-vivo device location
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
US7970455B2 (en) 2004-05-20 2011-06-28 Spectrum Dynamics Llc Ingestible device platform for the colon
WO2005113374A2 (en) 2004-05-21 2005-12-01 Given Imaging Ltd. Device, system and method for in-vivo sampling
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008526418A (ja) * 2005-01-18 2008-07-24 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 放射線を放出するための電子制御されるカプセル
EP1841490A2 (en) * 2005-01-18 2007-10-10 Koninklijke Philips Electronics N.V. Electronically controlled capsule
ES2424042T3 (es) 2005-06-07 2013-09-26 Esbatech - A Novartis Company Llc Anticuerpos estables y solubles que inhiben TNF±
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
US20070027362A1 (en) 2005-07-27 2007-02-01 Olympus Medical Systems Corp. Infrared observation system
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CN101472639A (zh) * 2006-06-20 2009-07-01 皇家飞利浦电子股份有限公司 用于治疗胃肠疾病的电子胶囊
JP2009541018A (ja) * 2006-06-23 2009-11-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 薬剤投与システム
US20080112885A1 (en) 2006-09-06 2008-05-15 Innurvation, Inc. System and Method for Acoustic Data Transmission
RU2009120512A (ru) 2006-10-31 2010-12-10 Конинклейке Филипс Электроникс Н.В. (Nl) Конструкция глотаемого дозирующего устройства с множеством форсунок для выпуска лекарств в желудочно-кишечный тракт
EP2125076B1 (en) * 2007-02-26 2012-06-20 Duocure, Inc. Spray administration of compositions including active agents such as peptides to the gastrointestinal tract
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
EP2380564B1 (en) * 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
JP4932588B2 (ja) 2007-05-08 2012-05-16 オリンパス株式会社 画像処理装置および画像処理プログラム
US7842144B1 (en) 2007-06-01 2010-11-30 The United States Of America As Represented By The Secretary Of The Navy Methods of making double base casting powder
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
EP2254464B1 (en) 2008-02-18 2017-01-04 Medimetrics Personalized Drug Delivery B.V. Administration of drugs to a patient
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
US20100255508A1 (en) * 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR100931946B1 (ko) 2009-06-10 2009-12-15 주식회사 인트로메딕 캡슐 내시경에 의해 촬영된 이미지 데이터를 저장하고 있는 서버로부터 관심있는 데이터를 우선하여 단말기에 수신하여 확인할 수 있도록 하는 서버-클라이언트 시스템의 이미지 데이터 전송 프로세싱 방법
WO2011004395A1 (en) 2009-07-06 2011-01-13 Intas Biopharmaceuticals Limited Microemulsion formulation for biologicals
JP6030956B2 (ja) 2009-08-05 2016-11-24 テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド 胃腸管の異常の診断に使える情報を提供する方法と機器
US9026192B2 (en) 2009-11-24 2015-05-05 Given Imaging Ltd Device and method for in vivo imaging
EP2571573A4 (en) * 2010-03-17 2013-12-04 Photopill Medical Ltd PHOTOTHERAPY BY CAPSULE
AU2012204869B2 (en) 2011-01-04 2016-01-28 Charite Universitatsmedizin Berlin Modulators of IL-12 and/or IL-23 for the prevention or treatment of Alzheimer's disease
EP2661448A4 (en) 2011-01-07 2015-09-16 Abbvie Inc ANTI-IL-12 / IL-23 ANTIBODIES AND USES THEREOF
BR112013021863A2 (pt) 2011-03-03 2016-11-22 Apexigen Inc anticorpos anti-receptor il-6 e métodos de uso
WO2012137705A1 (ja) 2011-04-01 2012-10-11 オリンパスメディカルシステムズ株式会社 受信装置及びカプセル型内視鏡システム
US20140228715A1 (en) 2011-05-13 2014-08-14 The General Hospital Corporation Method and Apparatus for Delivering a Substance
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
WO2013080050A2 (en) 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
WO2013088444A2 (en) 2011-12-15 2013-06-20 Given Imaging Ltd. Device, system and method for in-vivo detection of bleeding in the gastrointestinal tract
US9795330B2 (en) 2011-12-15 2017-10-24 Given Imaging Ltd. Device, system and method for in-vivo detection of bleeding in the gastrointestinal tract
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
FR2986432B1 (fr) 2012-02-06 2014-03-14 Univ Lille Ii Droit & Sante Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17
EP2819584B1 (en) 2012-02-17 2020-04-08 Progenity, Inc. Ingestible medical device
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
RU2015155552A (ru) 2013-05-24 2017-06-27 Нестек С.А. Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
US9324145B1 (en) 2013-08-08 2016-04-26 Given Imaging Ltd. System and method for detection of transitions in an image stream of the gastrointestinal tract
WO2015059569A1 (en) 2013-09-26 2015-04-30 Medimetrics Personalized Drug Delivery, B.V. Delivery capsule with threshold release
US20160249793A1 (en) 2013-12-27 2016-09-01 Kang-Huai Wang Capsule Camera Device with Multi-Spectral Light Sources
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
US10219748B2 (en) 2014-01-22 2019-03-05 Nutech Ventures Gastrointestinal sensor implantation system
US10281017B2 (en) 2014-05-30 2019-05-07 Schaeffler Technologies AG & Co. KG Torque converter including spherical clutch
AU2015319850B2 (en) 2014-09-25 2019-09-26 Bt Bidco, Inc. Electromechanical pill device with localization capabilities
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
CN104473611B (zh) 2015-01-19 2018-01-30 吉林大学 具有超声波定位功能的胶囊内窥镜系统
CN105877685B (zh) 2015-01-26 2019-03-15 香港中文大学 内窥镜胶囊和内窥镜系统
JP6895421B2 (ja) 2015-03-31 2021-06-30 ブイエイチスクエアード リミテッド ポリペプチド
WO2016193964A1 (en) 2015-05-31 2016-12-08 Check-Cap Ltd. Drug delivery capsule
JP2017012395A (ja) 2015-06-30 2017-01-19 富士フイルム株式会社 内視鏡システム及び内視鏡システムの作動方法
CA3034267A1 (en) 2016-08-18 2018-02-22 Mitchell Lawrence Jones Systems for obtaining samples using ingestible devices
US20180070857A1 (en) 2016-09-09 2018-03-15 Progenity Inc. Electromechanical ingestible device for delivery of a dispensable substance
CA3036334A1 (en) 2016-09-09 2018-03-15 Mitchell Lawrence Jones Systems and methods for extracting a sample from an ingestible device
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3047241A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Ingestible device recovery system
WO2018112425A1 (en) 2016-12-15 2018-06-21 Progenity Inc. Ingestible device and associated methods
EP3900613B1 (en) 2017-03-31 2023-12-27 Biora Therapeutics, Inc. Localization methods for an ingestible device

Also Published As

Publication number Publication date
JP2020501699A (ja) 2020-01-23
JP2023071838A (ja) 2023-05-23
CN110072551A (zh) 2019-07-30
AU2017376807A1 (en) 2019-06-13
US11597762B2 (en) 2023-03-07
JP7237834B2 (ja) 2023-03-13
CN110072551B (zh) 2023-05-23
WO2018112232A1 (en) 2018-06-21
CA3045475A1 (en) 2018-06-21
US20250230229A1 (en) 2025-07-17
EP3554540B1 (en) 2023-08-02
MX2019006823A (es) 2019-10-21
CN117045784A (zh) 2023-11-14
KR20190095931A (ko) 2019-08-16
EP3554540A1 (en) 2019-10-23
EP3554540C0 (en) 2023-08-02
BR112019011702A2 (pt) 2019-10-22
US20200262908A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
US20250230229A1 (en) Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
AU2023201348B2 (en) Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
AU2017378393B2 (en) Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
US11596670B2 (en) Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
EP4233902A2 (en) Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20200094031A1 (en) Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
WO2019246271A1 (en) Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20240335644A1 (en) Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11134889B2 (en) Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
WO2018183932A1 (en) Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2018112237A1 (en) Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
WO2018112256A1 (en) Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BIORA THERAPEUTICS, INC.

Free format text: FORMER NAME(S): PROGENITY INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BT BIDCO, INC.

Free format text: FORMER OWNER(S): BIORA THERAPEUTICS, INC.